N/A N=60 Cognitive Reappraisal Training for Borderline Personality
Borderline Personality Disorder
Primary: Change in PINES Network Activity — 0.15; 0.14; 0.12; 012 BOLD Signal
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=56 Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
Zika Virus
Primary: Number of Participants With Solicited Local and General Adverse Events (AEs) — 10; 5; 8; 5 Participants
N/A N=455 Implementation of Function Focused Care in Acute Care
Dementia · Acute Medical Event · Hospitalization
Primary: The Barthel Index — 49.2; 54.9; 52.0; 58.7 score on a scale — p=<.05
Phase 2 N=66 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
Group B Streptococcus Infections
Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Primary Dose: Non-Pregnant Participants Stage 1 — 27.3; 27.3; 13.6; 22.7 Percentage of…
N/A N=115 Artificial Urinary Sphincter Clinical Outcomes
Stress Urinary Incontinence
Primary: Number of Subjects With Reduction in 24 Hour Pad Weight Test at 12 Months — 91 Participants — p=< 0.001
Phase 3 N=1,153 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Atopic Dermatitis
Primary: Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events — 2.1; 4.5 percentage of participants
N/A N=276 A TargEted MAnageMent Intervention for Reducing Stroke Risk Factors in High Risk Ugandans
Stroke
Primary: Change From Baseline Systolic Blood Pressure (BP) at 6 Months — 145.7; 141.9; 137.4; 141.1 millimeters of mercury (mmHg)
Phase 2 N=17 Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
Chronic Intestinal Pseudo-obstruction
Primary: Mean Change in Weekly Global Gastrointestinal Symptoms Average Index Score (WGGSAIS). — -0.424; -0.185 score — p==0.1279
N/A N=77 Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function
Gastrointestinal Diseases · Ileus Paralytic · Ileus
Primary: GI Functional Recovery — 47.94 hours
Phase 3 N=184 A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) Per Independent Review Committee (IRC) — 2.4; 29.5 Months
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 4 N=282 A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Type 2 Diabetes
Primary: Change From Baseline in HbA1c — -1.59; -0.69 percentage of HbA1c — p=<0.0001
Phase 3 N=2,516 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
Asthma
Primary: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) — 62; 110 Participants — p=<0.001
N/A N=15 Self-Administered Interactive Exercise Program (Tele-Exergame)
Mild Cognitive Impairment (MCI) · Mild Alzheimer Disease · Memory Deficits
Primary: Percentage Change in Cognitive Function at 6 Weeks Compared to Baseline — 9.7 percentage change
N/A N=144 Effects of Aromatherapy on Patient Satisfaction With Surgical Abortion at Less Than 10 Weeks Gestation
Surgical Abortion · Patient Satisfaction · Anesthesia
Primary: Patient Satisfaction With Anesthesia — 0.72; 0.46 score on a scale